Related Experiment Videos
Results of intensive long-term treatment of familial hypercholesterolemia
K Retterstøl1, M Stugaard, C Gørbitz
1Medical Department A, Rikshospitalet, Oslo, Norway.
Insights
Long-term lipid-lowering therapy for familial hypercholesterolemia (FH) is effective and well-tolerated. However, current intensive treatments are often insufficient to reach target LDL cholesterol levels, necessitating more potent agents.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Familial hypercholesterolemia (FH) is a genetic disorder leading to high LDL cholesterol and premature cardiovascular disease.
- Long-term outcomes and treatment adherence in FH patients require further investigation.
Purpose of the Study:
- To evaluate the long-term effects of lipid-lowering therapies in FH patients.
- To assess quality of life, treatment compliance, and clinical outcomes post-intervention.
Main Methods:
- Follow-up examination of 57 FH patients 5.5 years after a 1-year trial of lovastatin, cholestyramine, probucol, or omega-3 fatty acids.
- Assessment of quality of life, treatment adherence, adverse events, and clinical outcomes.
Main Results:
- Lipid-lowering therapy significantly reduced total cholesterol (36%), LDL cholesterol (38%), and triglycerides (20%), while increasing HDL cholesterol (8%).
- Coronary events decreased from 27 to 12 per 1,000 patient-years after treatment initiation.
- Despite good compliance and sustained efficacy, intensive therapy was insufficient for many patients to reach LDL cholesterol goals (< 4.0 mmol/L).
Conclusions:
- Long-term intensive lipid-lowering therapy is feasible and effective in FH outpatients.
- Significant challenges remain in achieving therapeutic LDL cholesterol targets for many FH patients.
- Development of more potent lipid-lowering agents is crucial for optimal FH management.
Abstract:
Fifty-seven patients with familial hypercholesterolemia (FH) with mean age of 48 years (range 30 to 69), participated in a follow-up examination 5.5 years after the completion of a 1-year trial with lovastatin, cholestyramine, probucol, or omega-3 fatty acids. The goals were to record quality of life, compliance to treatment, adverse effects, and clinical outcome. The quality of life was similar to that in a Norwegian reference population. The factors causing most distress to patients were keeping a diet low in saturated fats, taking medication, and fear of death. The medication was mostly prescribed in maximum dosages. At follow-up, the reduction in total cholesterol was 36% (p < 0.05), low-density lipoprotein (LDL) cholesterol 38% (p < 0.05), triglycerides 20% (p < 0.05) compared with being on diet therapy only. High-density lipoprotein (HDL) cholesterol increased 8% (p < 0.05). Intake of saturated and monounsaturated fat increased 1.5% and 1.7% (p < 0.05), respectively; polyunsaturated fat was unchanged. Three patients experienced myocardial infarction, of whom 2 died and 1 developed angina pectoris. Before the start of lovastatin treatment, 27 coronary events occurred per 1,000 patient-years in this group compared with 12 events per 1,000 patient-years thereafter. Of 28 patients reporting adverse events, 4 discontinued lovastatin and 3 discontinued cholestyramine. Several practical and psychological difficulties were associated with FH. Long-term intensive lipid-lowering therapy was possible in FH outpatients without loss of effect and with good compliance to therapy. Intensive therapy, today is, however, not sufficient for many FH patients to reach a therapeutic goal of LDL cholesterol < 4.0 mmol/L. More potent lipid-lowering agents are needed.